Monograph Title | Section | Source Publication | Page Number | Errata Post Date | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication Sort descending | Description |
---|---|---|---|---|---|---|---|---|
N-Benzoyl-L-arginine Ethyl Ester Hydrochloride | REAGENT SPECIFICATIONS | USPNF Online | Online | 30-Sep-2022 | 1-Dec-2022 | NA | NA | Change Crystallized Trypsin (USP Monograph). to: Trypsin (USP Monograph). |
GLYCYL-L-TYROSINE | IMPURITIES/Related Compounds | USPNF Online | Online | 24-Feb-2023 | 1-Jun-2023 | NA | NA | In Buffer solution: Change Dissolve 6.84 g of potassium phosphate in 1000 mL of water. to: Dissolve 6.84 g of monobasic potassium phosphate in 1000 mL of water. |
UREA C 13 | IMPURITIES | USPNF Online | Online | 25-Aug-2023 | 1-Sep-2023 | NA | NA | In Isotopic Purity/Chromatographic system: Change Flow rate: Flow rate to: Flow rate: 1 mL/min |
METHYLNALTREXONE BROMIDE | CHEMICAL INFORMATION | USPNF Online | Online | 23-Feb-2024 | 1-Mar-2024 | NA | NA | Correct the chemical structure |
AMMONIUM GLYCYRRHIZATE | CHEMICAL INFORMATION | USPNF Online | Online | 24-Jun-2022 | 1-Jul-2022 | NA | NA | Change 840.08 to: 839.97 |
<871> SUTURES--NEEDLE ATTACHMENT | PROCEDURE | USPNF Online | Online | 29-Jul-2022 | 1-Aug-2022 | NA | NA | In Removable Needle Attachment: Change For USP sizes 5-0 through 2-0, to: For USP sizes 5-0 through 2, |
MESO-ZEAXANTHIN | COMPOSITION/Stereoisomeric Composition | USPNF Online | Online | 27-Jan-2023 | 1-Jun-2023 | NA | NA | In System suitability: Change [Note—The approximate relative retention times for (3S,3′S)-zeaxanthin, (3R,3′S-meso)-zeaxanthin, (3R,3′R)-zeaxanthin, and (3R,3′R,6′R)-lutein are 0.94… Read More |
ATORVASTATIN CALCIUM TABLETS | ASSAY/Procedure | USPNF Online | Online | 30-Jun-2023 | 1-Jul-2023 | NA | NA | In Analysis: Change Mr1 = molecular weight of atorvastatin, 558.64 Mr2 = molecular weight of atorvastatin calcium, 1155.34 to: Mr1 = molecular weight of atorvastatin, 558.65 M… Read More |
OLMESARTAN MEDOXOMIL TABLETS | PERFORMANCE TESTS | USPNF Online | Online | 17-Nov-2023 | 1-Dec-2023 | NA | NA | In Dissolution 〈711〉/Test 5/Apparatus 2: Change 50 rpm. Use peak vessels. to: 50 rpm. Use apex vessels. |
APREPITANT CAPSULES | PERFORMANCE TESTS/Dissolution <711> | USPNF Online | Online | 27-May-2022 | 1-Jun-2022 | NA | NA | Change Test 1 Dilute 1 mL of phosphoric acid with water to 1 L. to: Test 1 AND Change Dilute phosphoric acid: to: Dilute phosphoric acid: Dilute 1 mL of phosphoric acid with water to 1 L. |
DOXORUBICIN HYDROCHLORIDE FOR INJECTION | ASSAY/Procedure | USPNF Online | Online | 28-Oct-2022 | 1-Nov-2022 | NA | NA | In Analysis: Change P = potency of doxorubicin in USP Doxorubicin Hydrochloride RS (µg/mg) to: P = potency of doxorubicin hydrochloride in USP Doxorubicin Hydrochloride RS (µg/mg) |
CALCIUM LACTATE | CHEMICAL INFORMATION | USPNF Online | Online | 31-Mar-2023 | 1-Apr-2023 | NA | NA | Change Calcium lactate (1:2) hydrate to: Calcium lactate hydrate AND Change Calcium lactate (1:2) pentahydrate to: Calcium lactate pentahydrate |
FOSAMPRENAVIR CALCIUM TABLETS | PERFORMANCE TESTS | USPNF Online | Online | 25-Aug-2023 | 1-Sep-2023 | NA | NA | In Dissolution 〈711〉/Medium: Change 26.7 g/L of sodium acetate trihydrate in water. Add 133 mL of glacial acetic acid to this solution, and then dilute with water to 10 L; 900 mL. to: 0.02 M sodium acetate buffer, pH 3.5, prepared as follows.… Read More |
RIVASTIGMINE TARTRATE | ADDITIONAL REQUIREMENTS | USPNF Online | Online | 26-Apr-2024 | 1-May-2024 | NA | NA | In USP Reference Standards 〈11〉: Change USP Rivastigmine Tartrate R-Isomer RS to: USP Rivastigmine Tartrate R-Isomer RS (R)-3-[1-(Dimethylamino)ethyl]phenyl ethylmethylcarbamate, hydrogen tartrate. C14H22N2… Read More |
METHYLENE BLUE | IMPURITIES/Organic Impurities | USPNF Online | Online | 26-Aug-2022 | 1-Sep-2022 | NA | USPNF 2023 Issue 2 | In footnote a in Table 2: Change 3-(Dimethylamino)-7-(methylamino)-phenothiazine-5-ium chloride. to: 3-(Dimethylamino)-7-(methylamino)phenothiazin-5-ium chloride. |
METHYLENE BLUE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USPNF Online | Online | 26-Aug-2022 | 1-Sep-2022 | NA | USPNF 2023 Issue 2 | In USP Azure B RS: Change 3-(Dimethylamino)-7-(methylamino)-phenothiazine-5-ium chloride. to: 3-(Dimethylamino)-7-(methylamino)phenothiazin-5-ium chloride. |
ECONAZOLE NITRATE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USPNF Online | Online | 26-Aug-2022 | 1-Sep-2022 | NA | USPNF 2023 Issue 2 | In USP Econazole Related Compound C RS: Change 1-(4-Chlorobenzyl)-3-{2-[(4-chlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazol-3-ium nitrate (salt). C25H21Cl14N3O4 569.… Read More |
ROCURONIUM BROMIDE | CHEMICAL INFORMATION | USPNF Online | Online | 18-Nov-2022 | 1-Dec-2022 | NA | USPNF 2023 Issue 3 | Change 609.68 to: 609.69 |
ROCURONIUM BROMIDE | IMPURITIES/Organic Impurities | USPNF Online | Online | 18-Nov-2022 | 1-Dec-2022 | NA | USPNF 2023 Issue 3 | In footnote b of Table 1: Change 2β-(Morpholin-4-yl)-16β-(pyrrolidin-1-yl)-5α-androstan-3α,17β-diol. to: 2β-(Morpholin-4-yl)-16β-(pyrrolidin-1-yl)-5α-androstane-3α,17β-diol. |
AZITHROMYCIN FOR INJECTION | IMPURITIES | USPNF Online | Online | 28-Jul-2023 | 1-Aug-2023 | NA | USPNF 2024 Issue 2 | In footnote m in Table 2: Change (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-… Read More |
AZITHROMYCIN FOR INJECTION | ADDITIONAL REQUIREMENTS | USPNF Online | Online | 28-Jul-2023 | 1-Aug-2023 | NA | USPNF 2024 Issue 2 | In USP Reference Standards 〈11〉/USP Azaerythromycin A RS: Change 734.96 to: 734.97 AND In USP Azithromycin N-oxide RS: Change 764.98 to: 765.00 AND In USP N-Demethylazithromycin RS: Change 734.96 to: 734.97… Read More |